Last reviewed · How we verify
NXC736
At a glance
| Generic name | NXC736 |
|---|---|
| Sponsor | NEXTGEN Bioscience |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Oral NXC-736 in Adult Participants with Moderate and Severe Alopecia Areata (PHASE2)
- A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NXC736 CI brief — competitive landscape report
- NXC736 updates RSS · CI watch RSS
- NEXTGEN Bioscience portfolio CI